David Kallend Selected Research

dalcetrapib

1/2020	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.
10/2017	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
1/2016	Does Vascular Calcification Accelerate Inflammation?: A Substudy of the dal-PLAQUE Trial.
6/2015	Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
12/2014	Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
10/2013	Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
11/2012	Effects of dalcetrapib in patients with a recent acute coronary syndrome.
4/2012	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
10/2011	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
8/2011	Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Kallend Research Topics

Disease

12	Coronary Disease (Coronary Heart Disease) 01/2020 - 04/2004
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2009
9	Acute Coronary Syndrome 01/2020 - 12/2009
6	Inflammation (Inflammations) 01/2021 - 01/2011
3	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2004
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018 - 04/2005
3	Atherosclerotic Plaque (Atheroma) 01/2018 - 08/2011
3	Myocardial Infarction 10/2017 - 11/2012
3	Atherosclerosis 01/2017 - 04/2004
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 11/2018
2	Hypertension (High Blood Pressure) 06/2015 - 07/2009
2	Unstable Angina 06/2015 - 11/2012
2	Hypercholesterolemia 10/2004 - 05/2004
1	Liver Diseases (Liver Disease) 03/2022
1	Necrosis 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Homozygous Familial Hypercholesterolemia 01/2020
1	Prediabetic State (Prediabetes) 01/2020
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Heart Failure 10/2017
1	Left Ventricular Dysfunction 10/2017
1	Arteritis 01/2017
1	Injection Site Reaction 01/2017
1	Vascular Calcification 01/2016
1	Stroke (Strokes) 06/2015
1	Myocardial Ischemia (Ischemic Heart Diseases) 06/2015
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 12/2014
1	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 12/2014
1	Heart Arrest (Cardiac Arrest) 11/2012
1	Ischemic Stroke 11/2012

Drug/Important Bio-Agent (IBA)

14	dalcetrapibIBA 01/2020 - 07/2009
7	ALN-PCSIBA 03/2022 - 01/2017
7	LDL CholesterolIBA 01/2020 - 05/2004
7	Cholesterol Ester Transfer ProteinsIBA 01/2020 - 07/2009
7	LipidsIBA 12/2016 - 10/2004
5	HDL CholesterolIBA 01/2020 - 02/2010
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 06/2015
4	HDL LipoproteinsIBA 01/2020 - 11/2012
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2012
3	Small Interfering RNA (siRNA)IBA 01/2021 - 01/2019
3	Lipoproteins (Lipoprotein)IBA 12/2016 - 07/2014
3	Rosuvastatin Calcium (Crestor)FDA Link 10/2004 - 04/2004
2	oxidized low density lipoproteinIBA 01/2021 - 01/2019
2	MDCO-216IBA 01/2018 - 12/2016
2	Atorvastatin (Lipitor)FDA Link 06/2015 - 04/2004
2	Triglycerides (Triacylglycerol)IBA 06/2015 - 05/2004
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Antisense OligonucleotidesIBA 01/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020
1	Proprotein Convertase 9IBA 01/2020
1	omega-Chloroacetophenone (Mace)IBA 01/2020
1	SodiumIBA 01/2020
1	apolipoprotein A-I MilanoIBA 01/2018
1	Lipoprotein(a)IBA 01/2018
1	AldosteroneIBA 10/2017
1	Mineralocorticoid Receptor AntagonistsIBA 10/2017
1	Apolipoproteins AIBA 12/2016
1	CholesterolIBA 06/2015
1	Phytosterols (Plant Sterols)IBA 12/2014
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2014
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 12/2014
1	ApolipoproteinsIBA 07/2014
1	Peroxidase (Myeloperoxidase)IBA 10/2013
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2012
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2012
1	torcetrapibIBA 07/2009
1	Fenofibrate (CiL)FDA LinkGeneric 05/2004
1	Simvastatin (Zocor)FDA LinkGeneric 04/2004
1	Pravastatin (Pravachol)FDA LinkGeneric 04/2004

Therapy/Procedure

8	Therapeutics 01/2021 - 12/2009
2	Subcutaneous Injections 01/2020 - 01/2017
1	Intravenous Infusions 01/2018
1	Injections 01/2017
1	Resuscitation 11/2012
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 10/2004